MindWalk (NASDAQ:HYFT) Upgraded at JonesTrading

JonesTrading upgraded shares of MindWalk (NASDAQ:HYFT) to a strong-buy rating in a report released on Wednesday,Zacks.com reports.

Other equities research analysts have also recently issued research reports about the stock. HC Wainwright reaffirmed a “buy” rating on shares of MindWalk in a research note on Friday, March 13th. Weiss Ratings initiated coverage on shares of MindWalk in a research report on Wednesday, January 14th. They issued a “sell (d-)” rating for the company. UBS Group reissued a “buy” rating on shares of MindWalk in a research note on Friday, March 13th. Finally, Zacks Research upgraded shares of MindWalk from a “strong sell” rating to a “hold” rating in a research report on Monday, February 16th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $5.00.

MindWalk Price Performance

Shares of MindWalk stock opened at $1.33 on Wednesday. The firm has a market capitalization of $61.39 million, a PE ratio of -6.65 and a beta of 0.63. The firm’s 50 day moving average price is $1.23. MindWalk has a 12 month low of $0.40 and a 12 month high of $3.25. The company has a quick ratio of 3.64, a current ratio of 3.74 and a debt-to-equity ratio of 0.21.

MindWalk (NASDAQ:HYFT) last issued its quarterly earnings results on Thursday, March 12th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.02). MindWalk had a negative return on equity of 69.37% and a negative net margin of 66.79%.The firm had revenue of $3.00 million during the quarter, compared to analyst estimates of $3.50 million.

Institutional Trading of MindWalk

Large investors have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC increased its stake in shares of MindWalk by 8.4% in the 4th quarter. Renaissance Technologies LLC now owns 239,080 shares of the company’s stock worth $435,000 after acquiring an additional 18,600 shares during the last quarter. Jane Street Group LLC boosted its position in shares of MindWalk by 147.3% during the 4th quarter. Jane Street Group LLC now owns 161,202 shares of the company’s stock valued at $293,000 after acquiring an additional 96,018 shares during the last quarter. XTX Topco Ltd grew its holdings in shares of MindWalk by 118.6% in the fourth quarter. XTX Topco Ltd now owns 81,721 shares of the company’s stock valued at $149,000 after purchasing an additional 44,331 shares during the period. Bank of Montreal Can grew its holdings in shares of MindWalk by 81.0% in the fourth quarter. Bank of Montreal Can now owns 54,750 shares of the company’s stock valued at $100,000 after purchasing an additional 24,500 shares during the period. Finally, Bridgeway Capital Management LLC acquired a new stake in MindWalk during the fourth quarter worth about $91,000. 6.70% of the stock is currently owned by hedge funds and other institutional investors.

MindWalk Company Profile

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.